December 2020 – FarmaMondo SA announced an exclusive distribution of eteplirsen and golodirsen for certain patients with Duchenne muscular dystrophy

FarmaMondo is pleased to announce the launch of its brand new website! After months of hard work and dedication, we are delighted to officially announce th

November 2020 –  Dompé farmaceutici Spa and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMo

FarmaMondo and Zion Medical, an Israel startup pharma developer, signed today an agreement to establish a MAP for their novel drug Gammora. The product is

Amryt Pharma (www.amrytpharma.com/) has appointed FarmaMondo, the world’s leader in paid-access to unlicensed medicines, to exclusively manage the access o

While the world fights through COVID19 pandemic EUSA and Papa Giovani Hospital in Italy had initiated an observational study (SISCO trial – https://c

Amryt Pharma (www.amrytpharma.com/) has appointed FarmaMondo, the world’s leader in paid-access to unlicensed medicines, to exclusively manage the access o

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines has been appointed by EUSA Pharma to extend its current exclusive distrib

FarmaMondo has been appointed to exclusively manage the access of Carmustine Obvius to Italian healthcare providers looking to fulfill unmet medical needs

FarmaMondo SA announces it has established FarmaMondo Mexico, a fully owned subsidiary of FarmaMondo SA. The Mexican affiliate will upgrade the group’s cap

FarmaMondo Nordics Aps, a fully owned subsidiary of FarmaMondo SA, has received a GMP license from the Danish Medicines Agency. With this license in place,

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, will exclusively distribute Spectrila® via a Managed Access Program for

Merck’s Keytruda (Pembrolizumab) showed better results than chemotherapy at improving overall survival among first-line patients with non-small cell lung c

AstraZeneca’s Tagrisso has been approved by FDA as a first-line treatment for patients with metastatic non-small-cell lung cancer characterized by epiderma

FarmaMondo Team is pleased to inform you that  is attending Pharmagora Paris 2018. PharmagoraPlus has been the single largest conference and exhibition in

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Amomed Pharma to exclusively distribute Empressin®

Read the full interview, appeared on the magazine Healthcare and Life Sciences Review with our CEO, Mr. Jaron Spigel, regarding the uniqueness of FarmaMond

FarmaMondo SA announces it has established operations through its Global Access business unit into several south EU markets to allow direct to hospital sup

FarmaMondo Team is pleased to inform you that also for 2018 is attending Arab Health in Dubai. Arab Health is the largest gathering of healthcare and trade

FarmaMondo has recently hosted two days of medical workshops in Saint Petersburg and Moscow on November 9th and 10th 2017, as part of its support for

FarmaMondo SA announces it has established operations in Mexico to allow direct to hospital supply of unlicensed medicines, to cover spontaneous needs and

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by EUSA Pharma to exclusively distribute Qarziba® via

Following the successful and great experience of last 2 years’ participation FarmaMondo will return again to exhibit at EXPOPHARM 2017which will be held in

FarmaMondo is delighted to announce further expansion of its Russian operations. As of July 1st 2017 FarmaMondo Representative Office (Moscow, Russia) prov

Following the successful experience of last year’s participation FarmaMondo will return to exhibit at EXPOPHARM 2016 which will be held in Munich, Germany

FarmaMondo is proud to sponsor this unique event, Early Access Programmes Conference, held in London , UK, on 29th – 30 th November 2016. The only ev

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Ideogen Pharma to exclusively distribute Bicnu® (E

Farmamondo and AOP Orphan signs an exclusive registration, marketing and distribution agreement for AOP’s novel therapy Tetrabenazine indicated for Hunting

FarmaMondo approves Normokineztine in Russian Federation for Huntington disease patients. The product, license to FarmaMondo from AOP Orphan, has been appr

FarmaMondo announces the approval of Ellanse, an innovative product in the esthetic segment, by the Taiwan local regulatory body – TFDA – as a medical devi

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed to exclusively distribute Curefini® dermal ointment v

FarmaMondo is proud to announce that has been honored as “One of the Top trustworthy Swiss companies” by Dun & Bradstreet, a considerable busines

FarmaMondo completes a rebranding campaign for its Swiss local retail unit. The Swiss retail unit, known to be the corner stone of the FarmaMondo historica

FarmaMondo SA announces it has established operations in Argentina to allow direct to hospital supply of unlicensed medicines, to cover spontaneous needs a

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Orion Pharma to distribute Simdax® via a Managed A

FarmaMondo announces the establishment of its Brazilian subsidiary in Sao Paolo, Brazil. The subsidiary will facilitate the company’s vision and strategies

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by ADIENNE to distribute Tepadina® via a Managed Acce

FarmaMondo SA announces it has established operations in Beijing, China. The Chinese affiliate will upgrade the FarmaMondo group capabilities in providing